Alkermes (ALKS) Non-Current Deffered Revenue (2011 - 2022)
Alkermes (ALKS) reported Non-Current Deffered Revenue of $6.4 million for Q3 2022, down 50.25% year-over-year from $12.9 million in Q3 2021, and down 44.3% quarter-over-quarter from $11.5 million in Q4 2021.
Alkermes (ALKS) Non-Current Deffered Revenue (2011 - 2022) Analysis & Trends
Alkermes (ALKS) has 12 years of Non-Current Deffered Revenue data on file, last reported at $6.4 million in Q3 2022.
- Non-Current Deffered Revenue for Q3 2022 came in at $6.4 million, down 50.25% year-over-year; the trailing twelve-month figure through Sep 2022 was $6.4 million (down 50.25% YoY), and the FY2021 annual result was $11.5 million, down 29.92% from the prior year.
- Non-Current Deffered Revenue fell to $6.4 million in Q3 2022 per ALKS's latest filing, from $11.5 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $22.1 million in Q4 2019 and troughed at $5.0 million in Q3 2018.
- A 5-year average of $12.8 million and a median of $11.6 million in 2019 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2019 and 2022: Non-Current Deffered Revenue jumped 131.69% in 2019, then tumbled 50.25% in 2022.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $9.5 million in 2018, then jumped by 131.69% to $22.1 million in 2019, then decreased by 25.7% to $16.4 million in 2020, then slipped by 29.92% to $11.5 million in 2021, then slumped by 44.3% to $6.4 million in 2022.
- Business Quant data shows ALKS's Non-Current Deffered Revenue at $6.4 million in Q3 2022, $11.5 million in Q4 2021, and $12.9 million in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | - |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | - |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 6.40 Mn |
| Dec 31, 2021 | 11.49 Mn |
| Sep 30, 2021 | 12.86 Mn |
| Jun 30, 2021 | 14.17 Mn |
| Mar 31, 2021 | 14.75 Mn |
| Dec 31, 2020 | 16.40 Mn |
| Sep 30, 2020 | 18.64 Mn |
| Jun 30, 2020 | 18.88 Mn |
| Mar 31, 2020 | 21.16 Mn |
| Dec 31, 2019 | 22.07 Mn |
| Sep 30, 2019 | 11.19 Mn |
| Jun 30, 2019 | 11.62 Mn |
| Mar 31, 2019 | 11.34 Mn |
| Dec 31, 2018 | 9.53 Mn |
| Sep 30, 2018 | 5.01 Mn |
| Jun 30, 2018 | 5.86 Mn |
| Mar 31, 2018 | 6.17 Mn |
| Dec 31, 2017 | 5.66 Mn |
| Sep 30, 2017 | 6.13 Mn |
| Jun 30, 2017 | 6.78 Mn |